Stereotactic injection of DTI-015 into recurrent malignant gliomas: Phase I/II trial

Neoplasia

Volumn 5, Issue 1, 2003, Pages 9-16

  Hassenbusch, Samuel J ^a   Nardone, Emilio M ^a   Levin, Victor A ^a   Leeds, Norman ^a   Pietronigro, Dennis ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Direct Therapeutics Inc   (United States)

Author keywords

Clinical trial; GBM; Malignant glioma; Recurrent tumor; Stereotactic injection

Indexed keywords

ALCOHOL; CARMUSTINE; DTI 015; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATAXIA; BRAIN EDEMA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HEMATOMA; HEMIPARESIS; HEMIPLEGIA; HUMAN; HYDROCEPHALUS; LETHARGY; MALE; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEIZURE; SPEECH DISORDER; STEREOTAXIC SURGERY; SURVIVAL TIME; TUMOR VOLUME; URINE INCONTINENCE; VOMITING;

EID: 0037251695     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80012-x     Document Type: Article

References (17)

1. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, and Oldfield EH (1994). Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91, 2076-80.
2. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, and Zaknoen S (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12, 259-66.
3. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, and Schold SC (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group [see comments]. Lancet 345, 1008-12.
4. Kleinschmidt-Demasters BK (1986). Intracarotid BCNU leukoencephalopathy. Cancer 57, 1276-80.
5. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong SS, Cummins A, Paik CH, and Oldfield EH (1997). Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87, 586-94.
6. Laske DW, Youle RJ, and Oldfield EH (1997). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3, 1362-68.
7. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, and Oldfield EH (1995). Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82, 1021-29.
8. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, and Tomsak RT (1985). Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92, 402-406.
9. Morrison PF, Laske DW, Bobo H, Oldfield EH, and Dedrick RL (1994). High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266, R292-305.
10. Pietronigro D, Drnovsky F, Cravioto H, and Ransohoff J (2003). DTI-015 produces cures in T9 gliosarcoma. Neoplasia 5, 17-22.
11. Pietronigro D, Drnovsky F, Cravioto H, and Ransohoff J (1999). Stereotactic intratumoral injection of DTI-015 in a rat intracranial T9 gliosarcoma model. Proc Am Assoc Cancer Res 40, 583.
12. Pietronigro D, Frey K, Desmond T, Carter J, and Ross BD (2000). Rapid facilitated distribution of high 14C-BCNU concentrations following intratumoral injection of DTI-015 in rat 9L brain tumors. Proc Am Assoc Cancer Res 41, 523.
13. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, and Mahaley MS (1992). A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76, 772-81.
14. Simpson-Herren L, and Pietronigro D (1999). Intratumoral injection of DTI-015 in the Walker 256 subcutaneous model. Proc Am Assoc Cancer Res 40, 583.
15. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, and Yung WK (1999). Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17, 2572.
16. Wrensch MR, Minn Y, and Bondy M (2000). Epidemiology. In Neurooncology, The Essentials. M Bernstein, and M Berger (Eds). Thieme Medical Publishers, New York, pp. 2-17.
17. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, and Levin VA (2000). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83, 588-593.